← Eichor
Condition: Short Course Radiotherapy Scrt Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Short Course Radiotherapy Scrt

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Ca
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06864013A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer
Phase 2 · 1 location(s) · First Affiliated Hospital of Wenzhou Medical University · NCT07347951SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06850103SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Ruijin Hospital · NCT05576480SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
Phase 2 · 2 location(s) · Fujian Cancer Hospital · NCT06787183Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07646639Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06802666A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor a
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT07669220SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
NA · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07474103SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer(CRIT)
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT06908031SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07198165SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
Phase 2 · 1 location(s) · Shandong Provincial Hospital · NCT07284992SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
Phase 2 · 1 location(s) · Huazhong University of Science and Technology · NCT06516445SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC
Phase 3 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT07549399
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.